WT1-targeting T cells with azacitidine for AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new type of cell therapy for people with acute myeloid leukemia (AML) that has minimal residual disease (small amounts of cancer left after treatment). The therapy uses your own immune cells, modified to target a protein called WT1 on leukemia cells, and combines it with a drug called azacitidine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with AML, but not the M3 subtype (acute promyelocytic leukemia).
- You have a specific genetic marker (HLA-A*02:01) that makes this therapy suitable for you.
- Your leukemia cells show the WT1 protein.
- You have minimal residual disease (MRD) after initial treatment, meaning small amounts of leukemia are still detectable but you are in remission.
- You are overall healthy enough for treatment, with adequate heart, liver, and kidney function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests an immune “T cell” therapy made to recognize a specific leukemia target. It is for people whose acute leukemia has come back (relapsed) or did not fully respond after receiving a donor stem cell transplant.
This trial tests whether two drugs—ruxolitinib (a JAK inhibitor) and azacitidine (a low-dose chemotherapy)—can help prevent acute myeloid leukemia from coming back after you receive a stem cell transplant from an unrelated donor. The transplant uses a gentler conditioning approach to reduce side effects while fighting the cancer.
This trial is testing new drug combinations for people with newly diagnosed, high-risk AML who have not yet started treatment. It aims to find more effective therapies for this aggressive form of leukemia.
This trial tests a combination of chemotherapy drugs (venetoclax, cladribine, cytarabine, and azacitidine) for people newly diagnosed with specific types of acute myeloid leukemia (AML) who cannot have or choose not to have standard intensive chemotherapy.
This study tests DC-AML immune cells to help people with acute myeloid leukemia (AML) who are in remission but still show signs of leftover cancer cells or relapse risk. It may help the immune system attack AML cells, especially when a stem cell transplant is not an option.
This trial tests an injection of donor-derived immune cells (called RC1012) to lower the chance of AML coming back after an allogeneic stem cell transplant. It is aimed at people at higher risk of relapse once the transplant is completed.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.